) announced that its biologics and early-development services
unit -- BioReliance -- has introduced the updated Big Blue Mouse
Transgenic Rodent Mutation (TRM) assay. The assay is qualified to
meet the new Organization for Economic Co-Operation and
Development (OECD) Test Guideline 488 requirements for evaluation
of in vivo mutagenicity.
Big Blue assay meets the requirements of OECD Test Guideline
488 as well as additional regulatory guidelines and has been
recommended by various agencies and expert groups, including the
European Chemicals Agency, as an accepted assay for evaluating
mutagenicity in somatic and male germ cell tissues.
The assay service matches BioReliance's existing portfolio of
comprehensive genotoxicity testing methods and also offers a
unique confirmatory test for drugs and chemicals that initially
test positive for in vitro mutation assays.
Recently, Sigma-Aldrich's biological products and services
business - Sigma Life Science - launched a novel editing tool
Sigma CRISPRs. CRISPRs are a mammalian genome editing tool
appropriate for screening and exploratory studies. They are
inexpensive tools that can be used for the development of
targeted gene editing.
Sigma-Aldrich released its second quarter 2013 results in
July. The company posted adjusted earnings of $1.05 per share,
above the year-ago earnings of 97 cents. The results also beat
the Zacks Consensus Estimate of $1.03. The adjusted earnings
exclude other charges of 7 cents a share.
Profit as reported, rose roughly 3.5% year over year to $119
million (or 98 cents per share) in the quarter from $115 million
(or 94 cents per share) a year ago.
Net sales increased 3% year over year to $681 million in the
reported quarter, surpassing the Zacks Consensus Estimate of $679
million. Organic sales growth in the quarter was 4%, while
foreign exchange translation had a negative impact of 1%.
Sigma-Aldrich currently maintains a Zacks Rank #3 (Hold).
Other companies in the specialty chemical space with favorable
Zacks Rank are
Minerals Technologies Inc.
Sensient Technologies Corp.
). While Ferro carries a Zacks Rank #1 (Strong Buy), Minerals
Technologies and Sensient Technologies retain a Zacks Rank #2
FERRO CORP (FOE): Free Stock Analysis Report
MINERAL TECH (MTX): Free Stock Analysis
SIGMA ALDRICH (SIAL): Free Stock Analysis
SENSIENT TECH (SXT): Free Stock Analysis
To read this article on Zacks.com click here.